4月30日,乐普生物-B早盘上涨7.17%,报4.93港元。此轮上涨源于CG Oncology溶瘤病毒疗法CG0070在非肌层浸润性膀胱癌(NMIBC)三期临床试验中表现突出。CG0070单药疗效优于已获批疗法,获FDA突破性疗法认证。乐普生物拥有该药物在中国内地及港澳地区的开发和商业化权利,并已完成I期患者入组。此外,CG0070与普佑恒联合疗法针对BCG无应答NMIBC患者的I期试验已获...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.